The phase II study (NCT04482309) evaluated T-DXd (5.4 mg/kg once every 3 weeks) for HER2-expressing locally advanced or metastatic disease after at least one prior systemic treatment or without alternative treatments. Here, ERBB2 is linked to metastatic neoplasm.